

U-11

S P E C I F I C A T I O N

TITLE

"CALORICALLY DENSE NUTRITIONAL COMPOSITION"

BACKGROUND OF THE INVENTION

5 The present invention relates generally to the
treatment and nutritional support of patients. More
specifically, the present invention relates to
compositions for use in metabolically stressed patients
who need food restriction, but who do not necessarily
10 need increased contents of protein or special nutrients.

 Patients suffering from a loss of nutrients require
adequate nutritional support. A lack of adequate
nutritional support can result in malnutrition associated
complications. Thus, the goal of nutritional support is
15 to maintain body mass, provide nitrogen and energy in
adequate amounts to support healing, meet metabolic
demands characterized by the degree of stress, and
support immune function.

 A traditional form of nutritional support is
20 administering whole protein liquid feedings to the
patient to remedy the protein deficiency. However, some
patients requiring nutritional support have a compromised
absorptive capacity and thus cannot tolerate whole
protein liquid feedings as well as the long-chain fatty
25 acids and complex carbohydrates often present in such
whole protein feedings. Many diseases or their
consequences can cause malabsorption by impairment of
either digestion or absorption. For instance, patients
suffering from various types of inflammatory bowel
30 diseases typically cannot tolerate whole protein

feedings. As a result, semi-elemental and elemental protein diets were developed to treat such compromised patients.

However, in addition to the traditional
5 inflammatory bowel type patients, semi-elemental and elemental protein diets are currently being used in other patient segments. Specific conditions where these diets are being used include, for example, total parenteral nutrition patients receiving early transitional feedings,
10 acutely ill, and catabolic patients with increased nitrogen needs yet requiring an elemental diet.

Still further, many patients suffering from metabolic stress have a significant need for increased energy but often do not need or tolerate protein levels
15 beyond the normal requirement. Such patients also cannot tolerate the food volume necessary to deliver the energy they need. As a result, such patients need an elemental diet that provides calorically dense nutritional support while at the same time providing
20 moderate non-protein calories per gram of nitrogen. Although a variety of elemental and semi-elemental diets are currently being used in an attempt to treat and/or provide nutritional requirements to such patients, the inventors of the present invention do not believe the
25 needs of the metabolic stressed patients are being adequately met.

Accordingly, a need exists for an enteral nutritional formulation that meets the nutrient requirements of metabolically stressed patients without

unnecessarily subjecting such patients to high fluid volume treatments or formulations with increased protein levels.

SUMMARY OF THE INVENTION

5 The present invention provides a nutritional composition designed for metabolically stressed patients. To this end, the present invention provides nutritional support with formulations containing increased caloric density without elevated protein levels or excess fluid.

10 Pursuant to the present invention, an enteral composition includes a protein source comprising approximately 15% to 20% of the caloric distribution of the composition; a carbohydrate source; and a lipid source including a mixture of medium and long chain
15 triglycerides. Significantly however, the enteral composition, unlike prior compositions, has a caloric density of at least approximately 1.4 kcal/mL.

 In an embodiment, the hydrolyzed protein source is essentially 100% hydrolyzed whey protein.

20 In another embodiment, the lipid source of the composition includes at least 70% medium chain triglycerides.

 Still further, in another embodiment, the enteral composition of the present invention uniquely provides
25 calorically dense nutritional support while at the same time providing moderate non-protein calories per gram nitrogen (NPC/gN). Specifically, the present invention uniquely provides an enteral composition having a clinically acceptable ratio of non-protein calories per

03065363 03400

Moreover, due to the calorically dense nature of the composition of the present invention, the composition includes 100% of U.S. RDA in approximately 1500 kcal (1000 mL).

An advantage of the present invention is that it provides a nutritional composition that is ready-to-use, nutritionally complete, and contains proteins, lipids, vitamins and minerals in proportions suitable for older children (10+ years) and adults.

Another advantage of the present invention is that it provides a composition containing hydrolyzed whey protein, medium chain triglycerides and maltodextrin to enhance absorption in metabolically stressed patients.

Yet another advantage of the present invention is that it provides calorically dense nutritional support in the form of an elemental diet while at the same time providing a moderate NPC/gN ratio (non-protein calories
5 per gram nitrogen) of greater than at least approximately 90:1; for example about 140:1 to about 100:1.

Still further, an advantage of the present invention is the high caloric density will be especially useful for patients using the composition as a supplement
10 (i.e. HIV, cystic fibrosis) and as a nocturnal feeding (cystic fibrosis).

Additional features and advantages of the present invention are described in, and will be apparent from, the detailed description of the presently preferred
15 embodiments.

**DETAILED DESCRIPTION OF
THE PRESENTLY PREFERRED EMBODIMENTS**

Nutritional support of hospitalized as well as non-hospitalized patients requires prevention, recognition
20 and treatment of nutritional depletion that may occur with illness. The goals of nutritional support include stabilizing metabolic state, maintaining body mass, and/or facilitating growth in the presence of disease and gastrointestinal dysfunction.

Certain disease states exist that alter intake, absorption or metabolism. For example, certain health
25 conditions can impair the nutrient absorption and/or reduced gastrointestinal tolerance for diets which are based on whole proteins. These conditions include
30 patients suffering specifically from a compromised gut

function as well as patients, due to the severity of their condition, who are simply unable to tolerate whole protein diets.

Moreover, although certain patients with impaired
5 nutrient absorption and/or reduced gastrointestinal
tolerance may need fluid restriction, such patients do
not necessarily need the increased contents of protein
or special nutrients often present in existing elemental
diets. For instance, patient groups suffering from
10 Crohn's disease, cancer, cystic fibrosis, short bowel
syndrome, cerebral palsy, intractable diarrhea, gastric
reflux and HIV/AIDS often are classified as falling
within this group of patients. Likewise, patients
transitioning from parenteral feeding, are acutely ill,
15 or are considered post-surgery with cardiac/renal
complications requiring fluid control also have a need
for increased energy, but often do not need or tolerate
protein levels beyond normal requirements and cannot
tolerate the fluid volume necessary to deliver the needed
20 energy. For purposes of the present application, this
population of patients are generically referred to as
metabolically stressed patients.

The present invention provides a product that is
specifically directed to meet the nutritional needs of
25 metabolically stressed patients without elevated protein
levels or excess fluid. To this end, the present
invention provides calorically dense nutritional support
in the form of an elemental diet while at the same time
providing a moderate NPC/gN ratio. The nutritional diet

05063363 "02408

of the present invention preferably utilizes hydrolyzed whey protein, medium chain triglycerides and maltodextrin to enhance absorption in the metabolically stressed patients.

5 The protein source of the present invention provides approximately 15% to 20% of the total calories of the composition. In an embodiment, the protein source comprises approximately 16% (4 g/100 kcal) of the total calories of the composition. For adults and older
10 children (10+ years old), the protein concentration of the present invention is optimal for the moderate tissue repair needs of the targeted patient populations without imposing an undue nitrogen burden on renal function.

 The composition of the present invention is
15 preferably a peptide-based diet. In choosing the protein source, the present invention maximizes tolerance and absorption with the use of a hydrolyzed protein. In an embodiment, the protein source is enzymatically hydrolyzed whey protein. In a preferred embodiment, the
20 protein source is essentially 100% hydrolyzed whey protein. This type of protein source reduces the incidence of gastric reflux because gastric emptying is faster than with diets containing casein or whole whey.

 Also, the hydrolyzed whey protein of the present
25 invention serves as a rich source of the amino acid cysteine. Cysteine is a limiting amino acid for the formation of glutathione, and endogenous glutathione needs are greater in patients with chronic inflammatory and infectious conditions. The formula of the present

09025363 024000

invention preferably contains approximately 0.1% to 0.8% of calories as cysteine. In a preferred embodiment, the formula contains approximately 0.37% of calories as cysteine (925 mg/1000 calories).

5 The protein source may also include a portion as free amino acids. As with protein hydrolysate, the use of free amino acids reduces the potential for nutrient malabsorption. In an embodiment, the protein source contains from about 0.1% to 2.0% free amino acids.
10 Preferably, the protein source of the present invention contains less than about 2% free amino acids.

 Carbohydrates provides, in an embodiment, approximately 35% to 65% and, most preferably, approximately 40% to 60% of the caloric content of the
15 composition. In an embodiment, the carbohydrate source is approximately 51% of the caloric content of the composition. A number of carbohydrates can be used pursuant to the present invention. By way of example, the carbohydrates can be chosen from maltodextrin, corn
20 starch, sucrose and corn syrup solids.

 The lipid source of the present invention includes a mixture of medium chain triglycerides (MCT) and long chain triglycerides (LCT). The lipid source of the present invention is approximately 20% to about 50% of
25 the caloric content of the total composition; preferably about 25% to about 40%. In an preferred embodiment, the lipid source is approximately 33% of the caloric content of the composition.

050633631 021898

The lipid profile is designed to meet essential fatty acid needs (omega-3 and omega-6) while also keeping medium-chain triglyceride (MCT) content high and long-chain triglyceride (LCT) content low compared with prior formulas. Preferably, the lipid source comprises approximately 30% to 80% by weight MCTs. In a preferred embodiment, the lipid source of the present invention includes about 70% by weight from MCTs. Such MCTs are easily absorbed and metabolized in the metabolically stressed patient. The use of MCTs will also reduce the risk of potential for nutrient malabsorption. In a preferred embodiment, the medium chain triglyceride source is fractionated coconut oil.

The remainder of the lipid source is a mixture of LCTs. Suitable sources of long chain triglycerides are canola oil, corn oil, soy lecithin and residual milk fat and soybean oil. Pursuant to the present invention, the lipid profiles containing such LCTs are designed to have a polyunsaturated fatty acid omega-6 (n-6) to omega-3 (n-3) ratio of approximately 1:1 to 10:1; preferably about 6:1 to about 9:1. The proposed ratio of n-6:n-3 is designed to reduce the immune suppression associated with high omega-6 fatty acid concentration and provide adequate essential fatty acid. In an embodiment, the composition includes an omega-6 to omega-3 ratio of approximately 7:1.

Still further, the composition of the present invention contains a specialized vitamin and mineral profile. The composition includes at least 100% of the

United States Recommended Daily Allowance (USRDA) of vitamins and minerals in 1500 kcal. Moreover, the composition includes higher levels of key vitamins and minerals designed to support the metabolically stressed patients.

Specifically, pursuant to the present invention, the composition includes a high level of zinc. Preferably, at least approximately 225% of the USRDA of zinc is provided in the composition per 1500 Kcal. In an embodiment, 28.5 to 43.5 mg per 1500 calories of zinc are provided. In a preferred embodiment, 36 mg per 1500 calories of zinc is provided. The increased zinc compensates for zinc losses and provides increased zinc for tissue repair in a patient having increased healing requirements.

The composition of the present invention also includes an increased amount of vitamin C. At least approximately 750% of the USRDA of vitamin C is provided per 1500 Kcal. In an embodiment, 405 to 615 mg per 1500 calories of vitamin C is provided. In a preferred embodiment, 510 mg per 1500 calories of vitamin C is provided. Vitamin C is believed to accelerate the healing and granulation in patients with severe healing requirements. Vitamin C will support increased requirements/losses after surgery.

Pursuant to the present invention, the composition also includes increased amounts of selenium. Selenium deficiencies may develop in patients having elevated healing requirements. Pursuant to the present invention,

05035363 024533

at least approximately 60 to 90 mcg of selenium are provided in 1500 calories of formula. In a preferred embodiment, approximately 75 mcg of selenium per 1000 calories is provided.

5 Many of the commercially available enteral formulas contain far below the amount of carotenoids (beta-carotene) found in usual diets of normal healthy people. In fact, patients on liquid formula diets as their sole source of nutrition for one week or more have been found
10 to have plasma concentrations of carotenoids of only 8% to 18% as compared to controls consuming a free choice of diet. Bowen et al, "Hypocarotenemia in Patients Fed Enterally with Commercial Liquid Diets," *Journal of Parenteral and Enteral Nutrition*, 12(5): 44-49 (1988).
15 Those on enteral formulas for more than three weeks have negligible concentrations of any common serum carotenoids.

To meet these requirements, the present invention includes a source of beta-carotene. Beta-carotene is added to the composition to normalize beta-carotene serum plasma levels and to avoid beta-carotene deficiency in long term tube-fed patients. Beta-carotene also meets a portion of the required Vitamin A, thereby meeting micro-nutrient requirements in a small caloric volume. Moreover, beta-carotene is an important nutrient with anti-oxidant properties. The composition includes approximately 1.25 to 4.0 mg per 1500 kcal. In a preferred embodiment, the composition includes approximately 1.52 mg of beta-carotene per 1500 kcal of

5

10

15

25

to use and does not require reconstitution or mixing prior to use.

Unlike prior formulations, the present invention provides calorically dense nutritional support in the form of a elemental diet while at the same time providing a moderate NPC/gN ratio. To this end, the present invention preferably has a caloric density of approximately 1.4 to 1.8 kcal/mL. For example, the composition of the present invention has a caloric density of about 1.5 kcal/ml. The composition provides a moderate NPC/gN ratio of at least about 90:1. For example, the composition provides a NPC/gN ratio of about 140:1 to about 100:1. Preferably, the composition provides a NPC/gN ratio of 131:1.

Furthermore, unlike prior formulations, the present invention has a low osmolality of approximately 375 to 600 mOsm/kg H₂O in an unflavored product. The osmolality of the composition in a flavored product is approximately 500 to 700 mOsm/kg H₂O.

The composition of the present invention may be utilized to treat metabolically stressed patients. As used herein, metabolically stressed patients are patients who, due to either a disorder or condition, are unable to tolerate whole protein diets and need fluid restriction, while at the same time cannot tolerate elevated protein levels or excess fluid. For example, the present invention may be utilized to provide nutrition to critically ill patients transitioning from total parenteral nutrition therapy and acutely ill, catabolic

patients. Moreover, the present invention can be utilized to provide nutrition to patients suffering from the following conditions and/or diseases; Crohn's disease; cystic fibrosis; HIV/AIDS; cancer; patients of
5 post-surgery with cardiac/renal complications requiring fluid control; intractable diarrhea; short bowel syndrome; cerebral palsy; and gastric reflux.

Of course, it will be appreciated that a variety of formulations are possible in accordance with the present
10 invention. An example of a formulation in accordance with the present invention has a caloric density of about 1.5 kcal/ml. This is equivalent to 375 kcal/250 ml which will, in a preferred embodiment, be one unit (can or container) of product.

15 By way of example, and not limitation, an example of the suitable composition that may be used pursuant to the present invention is as follows.

The composition includes the following ingredients:
water; maltodextrin, enzymatically hydrolyzed whey
20 protein, medium-chain triglycerides (MCT source: fractionated coconut oil); corn starch; soy bean oil; soy lecithin; potassium phosphate; guar gum; calcium citrate; sodium phosphate; choline chloride; sodium chloride; calcium phosphate; calcium ascorbate; magnesium chloride;
25 potassium citrate; magnesium oxide; potassium chloride; taurine; citric acid; L-carnitine; zinc sulfate; ferrous sulfate; DL-alpha tocopherylacetate; nicotinamide; retinyl palmitate; calcium pantothenate; manganese sulfate; copper sulfate; pyridoxine hydrochloride;

riboflavin; thiamine; folic acid; cholecal ciferol; biotin; potassium iodide; beta carotene; sodium molybdate; chromium chloride; phylloquinone; sodium selenate; and cyanocobalamin.

5 The composition of the present invention may have the following nutrient composition (per 1500 calories (1000 ml)):

Nutrient Composition	Amount	% U.S. RDA*
Protein	60.0 g	132
Carbohydrate	191.0 g	**
Lipid***	58.5 g	**
Water	780 mL	**
Vitamin A	6000 IU	100
Beta-Carotene	3.0 mg	**
Vitamin D	600 IU	148
Vitamin E	45 IU	148
Vitamin K	75 mcg	**
Vitamin C	510 mg	840
Thiamine (B ₁)	3.0 mg	200
Riboflavin (B ₂)	3.6 mg	212
Niacin	42 mg	208
Vitamin B ₆	6 mg	300
Folic Acid	810 mcg	136
Pantoth. Acid	21 mg	140
Vitamin B ₁₂	12 mcg	132
Biotin	600 mcg	132
Choline	675 mg	**
Taurine	150 mg	**

Nutrient Composition	Amount	% U.S. RDA*
L-Carnitine	150 mg	**
Calcium	1000 mg	100
Phosphorus	1000 mg	100
Magnesium	400 mg	100
Zinc	36 mg	240
Iron	27 mg	148
Copper	3.0 mg	148
Manganese	4.0 mg	**
Iodine	225 mcg	148
Sodium	1020 mg	**
Potassium	1872 mg	**
Chloride	1740 mg	**
Chromium	60 mcg	**
Molybdenum	180 mcg	**
Selenium	75 mcg	**

* U.S. Recommended Daily Allowance for Adults & Children 4 or more years of age

** U.S. RDA not established

*** MCT provides 40.8 grams/1000 ml

In this example, the protein source comprises essentially 100% hydrolyzed whey protein. The carbohydrate source preferably includes approximately 70% to 95% maltodextrin, from about 5% to 15% corn starch, and up to about 20% sucrose; all % being on the basis of energy. Lastly, the lipid source preferably includes

approximately 70% MCTs, approximately 17% soybean oil; approximately 8% residual milk fats; and approximately 5% soy lecithin; all % being on the basis of energy.

By way of example, and not limitation, a
5 contemplative example illustrating the use of the present invention will now be given.

CONTEMPLATIVE EXAMPLE

06033363 024800
An experimental enteral product formulated according to the principles presented in this application
10 and essentially identical to the composition presented can be evaluated in a group of severely traumatized patients requiring early enteral feeding. Patients are fed by small bowel feeding tubes. The goal of this early feeding is to supply at least 60% of their calculated
15 energy needs. The primary data collected to evaluate this early feeding is to determine the tolerance to early and fairly aggressive feeding. Gastrointestinal symptoms such as diarrhea, bloating and cramping are tabulated and evaluated. Actual intake as a percentage of calculated
20 energy requirements is calculated for each patient on each day of feeding for five consecutive days. The nutritional goals set are 25 kcal/kg of estimated body weight/day and 1.6 grams of protein/kg/day.

25 Eighteen (18) patients, for example, are entered into the study and 16 of these patients complete the 5 days of feeding. For the first 24 hours of feeding, the average intake for the 16 patients is $65 \pm 12\%$ of the calculated nutritional requirement. The intake over the first 48 hours of feeding is $68 \pm 8\%$ of requirements.

Over the first 72 hours of feeding, the average intake is 73 \pm 6% of requirements and for the first 96 hours of feeding, the mean intake typically rises to 87 \pm 6% of requirement. Over the full five days of feeding evaluation, the average intake is 92 \pm 7% of the calculated energy requirements for the 16 patients who completed the full study period. Diarrhea develops in only one patient in the group and this generally persists for approximately 18 hours. No other gastrointestinal symptoms would typically be reported during the study period.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

1. An enteral composition designed for metabolically stressed patients comprising:

5

a carbohydrate source; and

a lipid source including a mixture of medium and long chain triglycerides, the enteral composition having a caloric density of at least approximately 1.4 kcal/mL.

10

15

4. The enteral composition of Claim 1 including 100% of U.S. RDA in approximately 1500 kcal.

20

comprises approximately 33% of the calorie distribution of the composition.

6. The enteral composition of Claim 1 wherein the protein source consists essentially of partially hydrolyzed whey proteins.

7. The enteral composition of Claim 1 wherein the composition includes per 1500 kcal of composition:

a zinc source providing from approximately 28.5 to 43.5 mg;

a vitamin C source providing from approximately 405 to 615 mg;

a selenium source providing from approximately 60 to 90 mg;

a taurine source providing from approximately 120 to 180 mg; and

a L-carnitine source providing from approximately 120 to 180 mg.

8. The enteral composition of Claim 1 further including a source of beta-carotene.

9. A method for providing nutrition to a metabolically stressed patient comprising the step of

a protein source comprising approximately 15% to about 20% of the calorie distribution of the composition;

a lipid source including a mixture of medium and long chain triglycerides, the enteral composition having a caloric density of at least approximately 1.4 kcal/mL.

11. The method of Claim 9 wherein the composition provides a ratio of non-protein calories per gram nitrogen of at least approximately 90:1.

13. The method of Claim 9 wherein the composition is fed through a tube to the patient.

20 14. The method of Claim 9 wherein the
composition contains approximately 0.37% of the calories
as cysteine.

a zinc source providing from approximately 28.5 to 43.5 mg;

a selenium source providing from approximately 60 to 90 mg;

a L-carnitine source providing from approximately 120 to 180 mg.

15 17. An enteral composition for a metabolically
stressed patient comprising:

about 15% to about 20% of the calorie distribution
of the composition of partially hydrolyzed whey protein;

a carbohydrate source; and

20 a lipid source including a mixture of medium and long chain triglycerides;

the composition having a caloric density of at least about 1.4 kcal/ml and a ratio of non-protein calories per gram of nitrogen of at least about 90:1.

18. The enteral composition of Claim 17 wherein
5 the carbohydrate source provides about 35% to about 65%
of calories and the lipid source provides about 20% to
about 50% of calories.

19. The enteral composition of Claim 17 which includes, per 1500 kcal:

10 a zinc source providing from about 28.5 to about
43.5 mg zinc;

a vitamin C source providing about 405 to 615 mg
vitamin C;

a selenium source providing about 60 to about 90 mg

15 selenium;

a taurine source providing about 120 to about 180 mg taurine; and

an L-carnitine source providing about 120 to about 180 mg L-carnitine.

20 20. The enteral composition of Claim 17 which
has a caloric density of about 1.4 to about 1.8 kcal/ml.

The present invention provides an enteral composition and method for providing nutrition to metabolically stressed patients. Pursuant to the present invention, the enteral composition has an increased caloric density of approximately 1.4 to 1.8 kcal/mL. The enteral composition includes a peptide based protein source, a lipid source, and a carbohydrate source.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"CALORICALLY DENSE NUTRITIONAL COMPOSITION"

Case No. P97,1036, the specification of which

(check one) X is attached hereto.
 was filed on _____, as
Application Serial No. _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent Office all information which is known to me to be material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).¹

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, and I believe that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as identified below:

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate listed below

Prior Foreign Application(s)

Number	Country	Date
--------	---------	------

N/A

and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the above listed application on which priority is claimed:

Prior Foreign Application(s)

Number	Country	Date
--------	---------	------

N/A

¹ (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a *prima facie* case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A *prima facie* case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

If no priority is claimed, I have identified all foreign patent applications filed prior to this application:

Prior Foreign Application(s)

Number

Country

Date

N/A

And I hereby appoint Messrs. John D. Simpson (Registration No. 19,842), Lewis T. Steadman (17,074), Dennis A. Gross (24,410), Robert M. Barrett, (30,142) Steven H. Noll (28,982), Kevin W. Guynn (29,927), Robert M. Ward (26,517), Brett A. Valiquet (27,841), Edward A. Lehman (22,312), David R. Metzger (32,919), James D. Hobart (24,149), Melvin A. Robinson (31,870), John R. Garrett (27,888), Brian M. Mattson (35,018), Paula J. Kelly (37,624), John W. Cornell (30,619), Robert J. Depke (37,607), Joseph P. Reagen (35,332), Michael R. Hull (35,902), Michael S. Leonard (37,557) and Marvin Moody (16,549) all members of the firm of Hill, Steadman & Simpson, A Professional Corporation

Telephone: 312/876-0200 Ext. 3060

my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and direct that all correspondence be forwarded to:

Hill & Simpson
A Professional Corporation
85th Floor Sears Tower, Chicago, Illinois 60606

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor DAVID A. MARK

Inventor's signature DA A Mark Date 2/5/98
Residence 714 S. Elmwood, Oak Park IL 60304
Citizenship United States
Post Office Address _____

Full name of second joint inventor,
(if any) DIANA TWYMAN

Inventor's signature [Signature] Date 2/16/98
Residence 344 W. DICKENS #7
Citizenship United States
Post Office Address CHICAGO, IL 60614

Full name of third joint inventor,
(if any) TOM MICHALSKI

Inventor's signature [Signature] Date 2/13/98
Residence 33094 Ashley Drive, Grayslake, IL 60030
Citizenship United States
Post Office Address _____

0005363 021698